Skip to Content
Merck
All Photos(1)

Key Documents

V-025

Supelco

Vitamin D3 solution

1 mg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®

Synonym(s):

Vitamin D3 solution

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C27H44O
CAS Number:
Molecular Weight:
384.64
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material

Quality Level

form

liquid

feature

(Snap-N-Shoot®)
(Snap-N-Spike®)

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1 mg/mL in ethanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing
clinical testing

format

single component solution

storage temp.

−70°C

InChI

1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1

InChI key

QYSXJUFSXHHAJI-YRZJJWOYSA-N

Gene Information

human ... VDR(7421)

General description

Vitamin D3 or cholecalciferol is a form of vitamin D produced naturally by the skin when exposed to ultraviolet light. Vitamin D3 is also manufactured industrially to fortify foods or for use in vitamin supplements.

Application

This certified solution standard is suitable for use as a Snap-N-Spike® starting material in the preparation of calibrators or controls for clinical applications or Snap-N-Shoot® in quality control testing of vitamin supplements, fortified foods or pharmaceutical preparations.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

FlameExclamation mark

Signal Word

Danger

Hazard Statements

Hazard Classifications

Eye Irrit. 2 - Flam. Liq. 2

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

57.2 °F

Flash Point(C)

14.0 °C


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Stefan Pilz et al.
Hypertension (Dallas, Tex. : 1979), 65(6), 1195-1201 (2015-03-25)
Vitamin D deficiency is a risk factor for arterial hypertension, but randomized controlled trials showed mixed effects of vitamin D supplementation on blood pressure (BP). We aimed to evaluate whether vitamin D supplementation affects 24-hour systolic ambulatory BP monitoring values
Anders Burild et al.
Steroids, 98, 72-79 (2015-03-01)
Information regarding the endogenous storages of vitamin D3 after cutaneous vitamin D synthesis compared to oral vitamin D3 supplementation is sparse. Furthermore it is not known whether vitamin D3 can be stored for later use during periods of shortages of
Yuan-Hua Chen et al.
Toxicological sciences : an official journal of the Society of Toxicology, 145(1), 90-97 (2015-02-13)
Several reports demonstrated that maternal lipopolysaccharide (LPS) exposure at middle gestational stage caused neural tube defects (NTDs). This study investigated the effects of supplementation with vitamin D3 (VitD3) during pregnancy on LPS-induced NTDs. Pregnant mice except controls were ip injected
Robert Scragg et al.
Hypertension (Dallas, Tex. : 1979), 64(4), 725-730 (2014-07-02)
Previous randomized controlled trials of vitamin D supplementation and blood pressure (BP) mainly have given vitamin D for short periods (<6 months) or at low doses (400 IU per day). This study aims to determine whether long-term high-dose vitamin D
Sagar U Nigwekar et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 60(1), 139-156 (2012-05-09)
The development of chronic kidney disease (CKD) is accompanied by a progressive decrease in the ability to produce 1,25-dihydroxyvitamin D. Pharmacological replacement with active vitamin D therefore has been a cornerstone of secondary hyperparathyroidism therapy in the end-stage renal disease

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service